Skip to content

A Randomized Controlled Trial and Clinical Mechanism Exploration of the Golden Needle “Tiao Shen”Acupuncture Intervention for amnesia mild cognitive impairment

A Randomized Controlled Trial and Clinical Mechanism Exploration of the Golden Needle “Tiao Shen”Acupuncture Intervention for amnesia mild cognitive impairment

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074888
Enrollment
Unknown
Registered
2023-08-18
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amnesia mild cognitive impairment

Interventions

Golden needle "Tiao Shen" accupuncture group:Golden needle "Tiao Shen" accupuncture
Filiform needle "Tiao Shen" accupuncture group:Filiform needle "Tiao Shen" accupuncture
Sham acupuncture group:Sham acupuncture
Healthy control group:No intervention

Sponsors

Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meets the aMCI diagnostic criteria; (2) The first onset, with a history of memory impairment of = 3 months, and no history of other neurological or psychiatric diseases; (3) Clinical Dementia Rating Scale (CDR) score 0.5 points; (4) Age range from 50 to 75 years old, regardless of gender; (5) Education experience = 1 year; (6) Volunteer participation, with informed consent signed by the individual.

Exclusion criteria

Exclusion criteria: (1) Previous intracranial hemorrhage or ischemic disease accompanied by focal neurological signs, with imaging evidence supporting cerebral hemorrhage,Tubular diseases (Fazekas score = 2 points); (2) Suffering from other nervous system disease that may cause brain function damage (such as epilepsy, depression, intracranial tumors,Kinsen's disease, metabolic diseases, encephalitis, multiple sclerosis, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.); (3) Cognitive impairment caused by other systemic diseases: such as liver dysfunction, renal dysfunction, thyroid dysfunction, severe anemia, folic acid and vitamin B12 deficiency, CO poisoning, special infections (such as syphilis, AIDS), alcohol and drug abuse; (4) Existence of mental and neurological developmental delays; (5) There are contraindications for magnetic resonance imaging examination; (6) Suffering from diseases that cannot cooperate in completing cognitive tests; (7) Have taken anti dementia treatment medication within one month, such as donepezil, galantamine, rivastigmine, memantine, etc; (8) Participants refused to sign a written informed consent form to participate in the study.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment,MOCA;

Secondary

MeasureTime frame
Functional Activities Questionnaire,FAQ;Hamilton Anxiety Scale;Hamilton Depression Scale;fMRI;

Countries

China

Contacts

Public ContactWang Xin

Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University

xinflare827@126.com+86 156 5260 8247

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026